Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (NASDAQ:SLDB), a precision genetic medicines company, will present data from its neuromuscular and cardiac programs at two major scientific conferences in October 2025. The company will participate in the World Muscle Society (WMS) Annual Congress in Vienna and the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Seville.

The presentations include an oral update on the INSPIRE DUCHENNE Phase 1/2 study of SGT-003 for Duchenne Muscular Dystrophy, and multiple poster presentations covering muscle integrity biomarkers, gene therapy developments, and cardiac research. The company will showcase data demonstrating the potential of their proprietary AAV-SLB101 capsid technology.

Solid Biosciences (NASDAQ:SLDB) will present data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, their next-generation gene therapy for Duchenne muscular dystrophy, at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG) in Italy.

The presentations will showcase Day 90 biopsy data and updated safety data as of August 12, 2025. The company highlights SGT-003's favorable liver tolerability and encouraging early biomarker signals. Additionally, their AAV-SLB101 capsid technology has been licensed to over 25 companies and institutions for targeted gene therapy applications.

Three poster presentations will be delivered on September 26, 2025, covering the INSPIRE DUCHENNE study updates, safety evaluation, and AAV-SLB101 insights.

Solid Biosciences (NASDAQ:SLDB) has entered into a non-exclusive worldwide licensing agreement with Kinea Bio for its proprietary next-generation capsid, AAV-SLB101. The agreement allows Kinea Bio to use AAV-SLB101 for developing KNA-155, a gene therapy targeting dysferlinopathy, a form of limb-girdle muscular dystrophy.

Under the agreement, Solid will receive an upfront payment and is eligible for development and sales milestones, plus tiered royalties on net sales. The AAV-SLB101 capsid has demonstrated enhanced muscle tropism and reduced liver biodistribution in preclinical studies and early clinical data from the ongoing Phase 1/2 INSPIRE DUCHENNE trial, where it has been well-tolerated in 15 participants as of August 12, 2025.

This marks another successful partnership for Solid's AAV-SLB101 platform, with over 25 agreements and licenses executed to date.

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines, has announced its participation in four upcoming investor conferences in September 2025. President and CEO Bo Cumbo will participate in fireside chats at the Citi Biopharma Back to School Conference (Sept 2), Cantor Global Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 8), and Baird Global Healthcare Conference (Sept 9).

All fireside chat sessions will be available via webcast on the company's investor relations website, with replays archived for 90 days. Management will also conduct one-on-one meetings with institutional investors during each conference.

Solid Biosciences (NASDAQ:SLDB) reported significant progress across its clinical pipeline in Q2 2025. The company's lead program SGT-003 for Duchenne muscular dystrophy has dosed 15 participants in the INSPIRE DUCHENNE trial with no serious adverse events reported. The company plans to initiate Phase 1b trials for both SGT-212 (Friedreich's Ataxia) and SGT-501 (CPVT) in Q4 2025.

The company's proprietary AAV-SLB101 capsid technology has garnered significant interest, with over 25 agreements or licenses executed. Financially, Solid ended Q2 with $268.1 million in cash, providing runway into H1 2027. Q2 2025 saw increased R&D expenses of $32.4 million (vs $19.5M in Q2 2024) and a net loss of $39.5 million (vs $25.1M in Q2 2024).

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines, has granted 55,450 restricted stock units (RSUs) to four new employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (NASDAQ:SLDB) has received FDA Fast Track designation for SGT-501, its novel gene therapy treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT). This designation adds to previously received FDA IND clearance, Orphan Drug, and Rare Pediatric Disease designations.

SGT-501 is designed as a first-in-class AAV-based gene therapy that delivers a functional CASQ2 gene to cardiac muscle cells, targeting the underlying causes of CPVT, a life-threatening cardiac condition. The therapy has received both FDA IND clearance and Health Canada CTA approval.

The company plans to initiate a Phase 1b clinical trial in Q4 2025, which will be a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and efficacy of SGT-501.

Solid Biosciences (NASDAQ:SLDB) has received both FDA IND and Health Canada CTA approvals for SGT-501, their first-in-class cardiac gene therapy designed to treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The therapy has secured Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.

CPVT is a rare, life-threatening genetic heart condition with no currently approved therapies. The company plans to initiate a Phase 1b clinical trial in Q4 2025 to evaluate SGT-501's safety, tolerability, and efficacy. The therapy targets the underlying disease mechanism by addressing abnormal calcium releases from the sarcoplasmic reticulum in the heart.

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of inducement awards to new employees. The company issued 105,330 restricted stock units (RSUs) to seven newly hired employees.

The RSUs will vest over a four-year period, with equal installments vesting annually on the grant date anniversary. The awards were granted under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.